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Introduction
For the past 15 years, numerous studies have been performed in different populations using both linkage and association approaches, to try to identify genes that might increase the individual's susceptibility to osteoporosis [1, 2] . Most of these studies did not give any conclusive results, and lacked replication due to reasons such as genetic heterogeneity between different populations and low sample power. Still such studies were useful in understanding better the complex pathophysiology of osteoporosis by identifying genes playing a role in various metabolic pathways and other mechanisms that might lead to disease. Linkage studies of monogenic bone diseases revealed several chromosomal regions putting into light various genes that were never thought to be involved in bone physiology such as the low density lipoprotein receptor-related protein (LRP)-5 and sclerostin (SOST) genes [3, 4] .
In a previous linkage study, performed on two Maltese families with a high incidence of osteoporosis, suggestive linkage to chromosome 11p12 was observed [5] . Fine-mapping reduced the linkage interval to a region between markers D11S1392 (50.64 cM) and D11S935 (52.94 cM), with highest total heterogeneity LOD and NPL (3.07 and 7.0, respectively) to marker D11S935. Although both families shared the same linkage interval, highest LOD scores were obtained to two different markers with a spacing of approximately 4 cM between them, showing also different inherited alleles, thus suggesting that different genes might be responsible for the disease in different families [5] . Highest LOD and NPL scores (1.77 and 5.9, respectively) were obtained for marker D11S1392 (50.64 cM) in Pedigree 2, while for Pedigree 1 highest scores were obtained to marker D11S4102 (54 cM). A total of 24 genes and four hypothetical proteins are known at the linkage interval from 49 to 55 cM on the deCode genetic map, of which tumour necrosis factor receptorassociated factor (TRAF)-6 and CD44 genes were the most likely candidates based upon prior knowledge of physiology. Sequencing the TRAF-6 gene, found between and approximately 1 cM away from both D11S935 and D11S4102, did not reveal any linked variations with disease. The other candidate gene at this locus is the CD44 gene which is found 1 cM away from D11S1392 (∼51 cM).
CD44 is a transmembrane glycoprotein existing in various isoforms, all consisting of a common hyaluronan-binding homology region, trans-membrane and cytoplasmic domains with most variant forms (CD44v) containing combinations of exons 6 to 15 (v1-v10) [6] . Osteoclast formation was inhibited by CD44 antibody suggesting its important role in bone physiology and as a potential therapeutic target for metabolic bone disease [7] . Expression of CD44 was observed to be induced at the onset of macrophage fusion where the intracellular domain of this molecule was found to play a major role in this process. Translocation of the CD44 intracellular domain to the nucleus also resulted in activation of NF-κβ which is essential for osteoclast activation [8] . Low molecular weight, but not high molecular weight, hyaluronic acid was observed to increase osteoclastogenesis induced by RANKL due to interactions with CD44 in bone marrow stromal cells which are involved in joint tissue destruction [9] . CD44 also plays an important role in cell migration, including that of osteoclasts, due to its interactions with osteopontin and other membrane proteins such as ezrin, radixin and moesin [10] . CD44 deficiency increased the severity of TNF-mediated arthritis due to deregulation of osteoclastogenesis [11] . Mice deficient in CD44 were more responsive to tumour necrosis factor (TNF) resulting in generalised osteopenia, while not affecting bone formation, suggesting the important role of CD44 in inflammatory bone loss. This increased responsiveness to TNF was associated with an increased activity of p38 mitogen-activated protein kinase which is negatively controlled by CD44 [12] .
In this study, sequencing of the CD44 gene found on chromosome 11p12 was performed in Pedigree 2 since this gene is found closer to D11S1392 which shows the highest LOD scores within this family. DNA sequencing of the CD44 gene revealed a rare sequence variant that was linked with the inherited haplotype in the majority of affected members.
Materials and methods

Subjects
Sequencing of the CD44 gene was performed in an extended family (Pedigree 2) participating in a previous linkage study [5] ( Fig. 1 and Table 1 ). Affected status was defined according to WHO criteria (t-score b −2.5) for generation II, while z-scores were used for younger individuals in generation III. As shown in Fig. 1 , a linked haplotype for markers D11S1392 and D11S935 (alleles 3 and 1, respectively) inherited identical by descent was observed in the majority of affected individuals.
A random sample of anonymous cord blood DNA (n = 126) obtained from newborns was used to estimate the frequency of the linked CD44 exon 9 variant in the population at birth. Cord blood was collected from neonates and taken to the Laboratory of Molecular Genetics, University of Malta, Malta for routine testing. Genomic DNA was extracted and purified using a salting out technique [13] .
All affected members (9 individuals) from Pedigree 1 were also tested for the CD44 exon 9 variant.
Sequencing of CD44 gene
Oligonucleotide primers were designed to amplify all coding regions including intron-exon boundaries and promoter region of the CD44 gene (MIM 107269) using transcript ENST00000278385) from the ENSEMBL database (http://www.ensembl.org) ( Table 2 ). Initial sequencing was performed using BigDye ® Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) in three affected (II:6, III:1, III:9) and one unaffected (III:6) individuals (with and without haplotype) and any sequence variants identified were further analysed in all family members by sequencing or by using restriction fragment length polymorphism (RFLP). The frequency of the identified linked variant in the CD44 gene was determined in the general Maltese population using allele specific amplification.
Allele specific amplification
The linked variant identified in exon 9 of the CD44 gene was analysed in the general population by polymerase chain reaction using confronting two-pair primers (PCR-CTPP) [14] . Two sets of primers were designed to amplify the specific alleles separately at optimum annealing temperature. A fragment of 163 bp was amplified using a forward primer with its last base at the 3′ end specific for the G allele while the A allele was detected by the amplification of 545 bp using a specific reverse primer. This reaction was carried out in a single tube where the forward primer used to amplify the A allele, together with the reverse primer of the G allele fragment, yielded another largest fragment of 666 bp that was used as an internal PCR control. The optimum PCR annealing temperature was that of 63°C. The best results were obtained when using 15 pmol of each primer for allele G (163 bp), together with 25 pmol of primers used for the A allele. PCR thermal profile used was as follows: hot-start for 15 min at 95°C followed by 30 cycles of 95°C for 30 s, 63°C for 15 s, 72°C for 90 s. A final extension for 5 min at 72°C was also performed. This method was validated against results obtained by direct DNA sequencing, while 20% of samples were repeated using separate PCR reactions for each allele.
RNA splicing analysis
An online application was used to identify any possible exon splicing enhancer (ESE) at this region as described by Cartegni et al. [15] (http://rulai.cshl.edu/tools/ESE2/index.html). The G/A variant was found to abolish an ESE motif (TGAGGA) for the SR protein (SRp55) with a score of 2.817 (threshold 2.676), in the presence of the A allele. The online application RESCUE-ESE (http://genes.mit.edu/fas-ess/) did not predict any possible ESEs at this locus [16] . A mini-gene system was used to test whether this linked variant found in exon 9 might affect splicing of pre-mRNA. Using this system, a hybrid construct made up of two vector β-globin exons flanking CD44 exon 9 and adjacent introns was created. Following transfection into mammalian cells, the construct was transcribed under the control of a SV40 promoter and spliced. The mRNA derived from this construct was extracted and reverse transcribed followed by specific amplification using cDNA as template and specific primers to β-globin exons (SD6 and SA2). The spliced transcripts were analysed by agarose gel.
DNA cloning
A 523 bp fragment containing the whole exon 9 and adjacent introns, was amplified by PCR using template DNA from a heterozygous family member for this variant, to isolate both mutated and normal alleles. The forward and reverse oligonucleotide primers were designed harbouring consensus sequences for endonucleases Xho I and Pst I, respectively at the 5′ end together with a non-complementary tail (Fwd: 5′-gTTCTCAATgCggAACTC-gAggTTTgTggTTCTgCCTTTgAC-3′ and Rev: 5′-gTTCTTgAACTTgCACTg-CAgAATTTgTgTgCgggTTTAgC-3′). The amplified fragment together with the exon-trapping vector pSPL3 (generously donated by Prof. Junko Oshima, Department of Pathology, University of Washington, Washington, USA) were digested and ligated overnight at 4°C, using T4 ligase (Promega Corporation, Madison, USA) ( Fig. 2 ). Transformation in DH5α was carried out using a heat shock protocol, first by incubating 25 μl cells with 2.5 μl ligation reaction for 20 min on ice. Following incubation on ice, the cells were subjected to heat shock treatment for 45-50 s at 42°C in a heating block and placed again on ice for another 2 min. Ampicillin free Luria Bertani (LB) broth (475 μl) was added into each tube and the cell suspension was incubated at 37°C for 1 h in a shaking incubator at 150 rpm. Following incubation, 150 μl from each suspension were plated onto LBAmp 100 selective plates and incubated at 37°C overnight. Selected clones were screened by digestion and DNA sequencing to check the integrity of the sequence and to select the two alleles. Purified plasmid DNA for transfections was extracted from a 100 ml culture grown for 16 h at 37°C using the PureYield ™ Plasmid Midiprep System (Promega Corporation, Madison, USA). DNA was adjusted to a concentration of 200 ng/μl.
Cell culture
Three different cell lines were used for transfections, including COS-7, HeLa (DSMZ, Braunschweig, Germany) and RAW264.7 (InterLab Cell Line Collection, Institute of Cancer Research, Genova, Italy). All cells were cultured in a high glucose Dulbecco Modified Eagle's Medium (DMEM) supplemented with 10% heat-deactivated foetal calf serum (FCS) (Sigma, Saint Louise, Missouri, USA). Incubation was carried out at 37°C in 5% CO 2 , splitting cells at 80% confluency. The day before transfection, 5 × 10 4 cells were added into each well of a 24-well plate. Each sample was assayed in triplicate, including positive (native pSPL3) and negative controls (cells without the addition of any DNA). Transient transfection was performed using the cationic lipid transfection reagent Tfx ™ -20 (Promega Corporation, Madison, USA) using 1 μg of each DNA construct and a charge ratio of DNA to transfection reagent of 1:2 for all cell lines. The mixture consisting of DNA constructs, transfection reagent and serum free DMEM was prepared in 1.5 ml microcentrifuge tubes and incubated for 10-15 min at room temperature. Culture medium was aspirated from cells and 200 μl of transfection mixture was added into each well. Incubation was carried out at 37°C for 1 h in 5% CO 2 . After incubation, 500 μl of complete medium was added into each well and plates were incubated for 24 h at 37°C in 5% CO 2 . RAW264.7 cells were also incubated in the presence of 10 ng/ml M-CSF, with or without 50 ng/ml RANKL (R&D Systems Ltd, Abington, UK). Stimulation with these cytokines was initiated 48 h before transfection.
Reverse transcription and PCR
After incubation, the cells were lysed and RNA extracted using RNeasy ® mini kit (Qiagen Gmbh, Germany) as instructed by the supplier. First strand cDNA was synthesised by reverse transcription using oligo-(dT) 16 , followed by PCR using specific primers for the splice donor (SD6) and acceptor (SA2) of the pSPL3 vector. The products were analysed using a 2% agarose gel electrophoresis and visualised under UV. All transcripts were excised from the gel and sequenced.
Results
Sequencing results
Sequencing CD44 revealed a number of intronic sequence variants, including two A/G changes (rs4756196 and rs3736812) and an A/C transversion in intron 16, none of which was observed to be inherited with the linked marker. A number of other variants were found in coding regions, including an A/G (rs9666607) and C/T (rs11607491) change in exon 10, both resulting in an amino acid change, which was not linked with the inherited haplotype. Another C/T synonymous variant (rs35356320) was detected in three affected and one unaffec- ted individual. A non-synonymous variant found in exon 12 (rs1467558) was only found in two affected members of this family. An interesting variant was detected in exon 9, a synonymous G/A transition (rs11033026), found 32 nucleotides upstream from the exon/intron junction. Sequencing the gene in all members of this family, revealed that all individuals carrying the linked STR allele 3 (Fig. 1) for marker D11S1392 were also heterozygous for this variant, suggesting that the two were linked. All affected members, with the exception of one (III:4), were heterozygous for both the STR allele and the A allele. This variant was not found in any of the non-affected family members, with the exception of two who also carried the linked STR allele (III:2 and III:7). Mean lumbar and femoral BMD (and z-scores) were compared between family members heterozygous for the A allele (n = 12) and homozygous GG (n = 5) ( Table 3 ). The independent sample t-test was used to test for significance. As shown in Table 3 , both lumbar and femoral BMD (including z-scores) were statistically significant when comparing GG with GA (p b 0.05).
Using allele specific amplification, 252 chromosomes were analysed in a random sample from the general Maltese population. Only 3 A alleles were identified in 3 heterozygous individuals, thus giving a population frequency of 2.38% and a minor allele frequency of 0.012 (1.19%). None of the nine affected members from the other pedigree (Pedigree 1), used in the previous linkage study [5] , was found to carry the A allele. Fig. 3 shows the results obtained from RT-PCR from cell lysates following transfections with the exon-trapping vector pSPL3. As shown in all three cell lines, two transcripts were amplified in the presence of the G allele (378 bp and 261 bp), while for the A allele the smaller transcript (261 bp) was weakly amplified in both COS-7 and HeLa cells but it was completely absent in RAW264.7 macrophages, even when stimulated by m-CSF, with or without RANKL. The sequencing of transcripts showed that the bigger fragment of 378 bp consisted of two vector exons, also harbouring exon 9 of CD44. The smaller fragment did not contain any portion of CD44 exon 9, and was entirely made up of vector exon sequences, suggesting skipping of exon 9. The presence of the G and A allele was confirmed when sequencing the bigger fragments.
RNA splicing analysis
Discussion
A large number of genes known to be involved in bone physiology have been studied to determine whether any variations within them might increase the individual's susceptibility to osteoporosis [1, 17] . In this study, the effects on pre-mRNA splicing of a known synonymous variant, found in exon 9 of the CD44 gene (rs11033026), are being reported. The A allele is in linkage with a haplotype inherited identical by descent in all affected family members, previously studied using qualitative linkage analysis [5] . Two clinically normal individuals (III:2 and III:7) also carried this allele in the heterozygous state, in linkage with the STR marker, suggesting incomplete penetrance possibly partly due to their relatively young age (23-and 33-year-old males). The BMD of individual III:7 might also have been positively influenced by his high body mass index (BMI) of 31.8 kg/cm 2 , although one cannot exclude the possibility of other gene modifiers being involved. Conversely, individual III:4 was affected, but did not carry the CD44 A allele or the linked STR allele, suggesting that low BMD in this individual might be due to environmental influences (phenocopy).
This variant was not found in nine affected individuals from Pedigree 1 used in the previous linkage study [5] , suggesting that it is increasing susceptibility to the disease only in Pedigree 2. Different mutations within the same or different gene/s present within the same linkage interval might be increasing the susceptibility to disease in these two families (showing allelic heterogeneity at the same locus).
The G/A variant (rs11033026) was only found in 2.38% of the general local population. When searching the NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11033026), the HapMap data, revealed that this variant was not reported in the European Caucasian population, but was found in Sub-Saharan Africans, African-Americans and Han Chinese from Beijing (minor allele frequencies 0.336, 0.115, and 0.012, respectively). This suggests a founder effect in the Maltese population, complementing other previously reported studies on other human diseases [18, 19] .
Since this variant does not result in an amino acid change, the hypothesis that it could affect pre-mRNA splicing was tested using an exon-trapping vector. In all three cell lines used, two transcripts were amplified in the presence of the wild-type G allele, one transcript harbouring the complete CD44 exon 9 and a smaller one consisting entirely of the two vector exons. In the presence of the A allele, the quantity of the shorter transcript relative to the longer one was less in both epithelial cells (HeLa and COS-7) but was completely absent in murine macrophages, suggesting that this variant could affect different tissues in a specific manner.
The presence of more than one transcript was expected since this gene is known to be transcribed and translated into a number of isoforms, due to alternative splicing of a large number of its exons [20] . Different CD44 isoforms were shown to have various functional roles in epidermal Langerhans and dendritic cells, such as in cell migration and antigen presentation. A pattern in expression was also observed during migration of these cells from the epidermis to the lymph nodes, where up to 100% of Langerhans cells in the dermis expressed v5, v6 and v9 while those in the lymph nodes expressed v4, v5 and v6 [21] . Shifts in expression between different CD44 isoforms were also reported to be useful as prognostic markers for various carcinomas, including osteosarcoma [22] .
The important role of the CD44 gene in the pathophysiology of osteoporosis is being documented for the first time. The role of CD44 in macrophage fusion is important since this process occurs during the differentiation of osteoclasts. Since macrophages are the precursors of osteoclasts, it could be hypothesised that this variant shifts the balance between different CD44 isoforms to that harbouring exon 9 (CD44v4) in osteoclasts, thus affecting their function and mechanisms, such as cell migration and fusion. Such a change in function could increase the risk of osteoporosis. The CD44v4 isoform (harbouring exon 9) was shown to be a major E-selectin ligand in breast cancer cells facilitating cell migration across the endothelium and hence enhancing metastasis [23] . Our study is of particular importance since a synonymous variant, located within the coding region of a gene, was found to increase the risk of osteoporosis in one family by affecting RNA splicing mechanism. This indicates that one cannot underestimate DNA variations found in non-coding regions and synonymous exonic variants. To our knowledge, to date, no variations that result in alternative splicing have been associated with osteoporosis, except for one variant found within intron 4 of the calcitonin-related peptide in an isolated case of an osteoporotic young male with very low calcitonin levels [24] . A number of variants were found to affect splicing in several genes that cause disease, such as the cystic fibrosis transmembrane conductance regulator (CFTR) gene [25] , neurofibromatosis type 1 [26] , type 5 collagen and Ehler-Danlos syndrome [27] , superoxide dismutase (SOD2) [28] and the ATP-binding cassette transporter A1 (ABCA1) [29] . RNA splicing can be affected by variations that alter the two dimensional structure of pre-mRNA molecule affecting its availability to interact with splicing factors or by increasing/decreasing recognition sites in both introns or exons for splicing enhancers (ESE) or silencers (ESS) [30] . A possible ESE motif that was predicted using a bioinformatics tool in the presence of the G allele was absent in the A allele (TGAGGA NTGAAGA), possibly affecting a splice site enhancer binding site that resulted in mRNA only harbouring exon 9 of this gene. The deleterious effects of missense mutations and the mechanisms by which these could result in aberrant splicing were described by other investigators. It was suggested that there might be a higher risk that functional ESEs cause aberrant splicing when these are found closer to the 3′ end of exons [31] . A common difficulty encountered when studying putative splicing mutations is to obtain RNA directly from the appropriate tissues to exclude cell specific effects, in this case, bone tissue. An alternative option is to use an exon-trapping system, as was used in this study which although reliable for initial evaluation of the splicing mechanism, does not always reflect the in vivo splicing mechanism [32] . A disadvantage of this system is that it is a hybrid, where in the ideal situation all exons and introns should come from the same gene. A major advantage, however, is that very short DNA fragments can be inserted avoiding the problem of handling thousands of nucleotides usually making up most mammalian introns [33] .
The importance of synonymous DNA variations together with those found in non-coding regions of genes, and the mechanisms by which such variants could be affecting susceptibility to disease, is slowly emerging. More evidence is showing that these variants can still affect the phenotype not only by altering RNA splicing but also by affecting protein folding, without a change in the amino acid sequence. Co-translational protein folding might be affected by timing as a result of a synonymous variant changing a commonly used codon into a rarer one, also coding for the same amino acid [34] . The time of translation is dependent upon the abundance of tRNA present in cells which correlates with codon usage in a tissue specific manner [35] . The rarer the codon, the less abundant is the corresponding tRNA, and thus the longer the time taken for translation to progress. Recent studies have shown that the enzyme specificity of the MDR1 gene was changed by the presence of a synonymous variant (C3435T), indicating that both function and 3-D structure of a protein could be altered without a corresponding change in the amino acid sequence [34, 36] . Such studies addressing the effects of these variants on protein function are important not only in the understanding of the pathophysiology of disease but also in the pharmacokinetics of different proteins. This could contribute towards the development of better targeted and individualised treatment regimens. These findings show that it is not enough to consider the DNA sequence of a gene. Studies have to investigate the functional role of variants at the RNA and protein levels, and also the epigenetic control of gene expression and post-translational modifications of proteins.
Further studies are needed to evaluate the role of the CD44 gene in bone physiology, osteoporosis, inflammatory bone loss and other bone diseases, including its possible role in metastasis of bone tumours.
